Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
BURLINGAME, Calif., Sept. 14, 2017 -- Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Five Prime Therapeutics, Inc. (NASDAQ:FPRX). The non-exclusive license grants Five Prime rights to use the AlivaMab Mouse for antibody drug discovery and development.
“Ablexis is pleased to add Five Prime to the list of leading biopharmaceutical companies that are using the AlivaMab Mouse,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “The AlivaMab Mouse is already being used by the majority of the world’s top 15 pharmaceutical companies, more than any other next generation antibody discovery platform. Now, with newly added licensing flexibility, Ablexis continues expanding the licensing of the AlivaMab Mouse for the rapid and efficient discovery of antibody drug candidates that meet target product profiles for activity, specificity and developability.”
About Ablexis, LLC
Ablexis, LLC created and commercializes the AlivaMab Mouse technology, a unique, patented next-generation transgenic mouse platform for human therapeutic antibody discovery. Ablexis has announced non-exclusive licensing of the AlivaMab Mouse technology to multiple companies and continues making the AlivaMab Mouse available via non-exclusive licenses. More information can be found by visiting the Company’s website at www.ablexis.com.
Ablexis Corporate Contact: Ablexis, LLC Larry Green, (415) 967-1220 [email protected] Ablexis Media Contact: Red House Communications Denise Powell, (510) 703-9491 [email protected]
